Literature DB >> 16886989

Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.

Ly Ngo1, Maromi Nei, Jon Glass.   

Abstract

A 40-year-old man with a left frontotemporal grade II oligodendroglioma developed seizures that were refractory to 14 antiepileptic medications, the ketogenic diet, and epilepsy surgery. With temozolomide therapy, his seizure frequency gradually changed from 30 partial seizures per day to a single simple partial seizure in 6 months. No additional therapeutic measures were introduced during this time. This reduction in seizure frequency appears attributable solely to temozolomide therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886989     DOI: 10.1111/j.1528-1167.2006.00597.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Meningeal melanocytosis: a possibly useful treatment for a rare primary brain neoplasm.

Authors:  Júlia Miró; Roser Velasco; Carles Majós; Miguel Gil; Susana Boluda; Jordi Bruna
Journal:  J Neurol       Date:  2011-01-20       Impact factor: 4.849

2.  Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.

Authors:  M Maschio; L Dinapoli; M Mingoia; F Sperati; A Pace; A Pompili; C M Carapella; A Vidiri; P Muti
Journal:  J Neurol       Date:  2011-06-16       Impact factor: 4.849

3.  Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.

Authors:  M Maschio; L Dinapoli; F Sperati; A Fabi; A Pace; A Vidiri; P Muti
Journal:  J Neurooncol       Date:  2011-08-17       Impact factor: 4.130

4.  Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.

Authors:  Marta Maschio; Loredana Dinapoli; Francesca Sperati; Andrea Pace; Alessandra Fabi; Antonello Vidiri; Paola Muti
Journal:  J Neurooncol       Date:  2010-11-25       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.